medigraphic.com
ISSN 0016-3813 (Impreso)

2003, Número 3

<< Anterior Siguiente >>

Gac Med Mex 2003; 139 (3)


Simposio de trasplante de células progenitoras hematopoyéticas. Una nueva perspectiva

I. Introducción
II. El trasplante de cordón: desde el laboratorio a la clínica
III. Trasplante de médula ósea: una nueva visión

Gómez-Morales E, Querol S, Ruiz-Argüelles GJ

Idioma: Español
Referencias bibliográficas: 40
Paginas: 105-112
Archivo PDF: 74.67 Kb.


FRAGMENTO

El trasplante de células hematopoyéticas (TCH) es un procedimiento con fines curativos, para trastornos por definición letales. Se aplica a enfermos con padecimientos inmunológicos, hematológicos benignos o malignos, tumores sólidos y trastornos autoinmunitarios, cuyas probabilidades de supervivencia libre de enfermedad sea menor a cinco años. Una de las principales limitantes para tener acceso a este tipo de tratamiento, es la disponibilidad de un donador compatible en el sistema de histocompatibilidad mayor (HLA), ya que sólo el 20% de los enfermos cuentan con un donador. La estrategia para poder vencer esta limitante, es contar con donadores no relacionados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Thomas ED, Blume KG. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 1999;5:341-346.

  2. Barker JN, Krepski TP, DeFor TE, Davis SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus none marrow. Biol Blood Marrow Transplant 2002;8:257-260.

  3. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood. Blood 2003;101:4233-4244.

  4. Ballen KK, Hicks J, Dharan B, Ambruso D, Anderson K, Bianco C, et al. Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. Transfusion 2002;42:1279-1284.

  5. Ballen K, Broxmeyer HE, McCullough J, Piaciabello W, Rebulla P, Verfaillie CM, Wagner JE. Current status of cord blood banking and transplantation in the United States and Europe. Biol Blood Marrow Transplant 2001;7:635-645.

  6. Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003;101:4711-4713.

  7. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood 2003;101(12):5061-5067.

  8. Goodwin HS, Bicknese AR, Chien S-N, Bogucki BD, Oliver DA, Quinn CO, Wall DA. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant 2001;7:581-588.

  9. Reed W, Smith R, Dekovic F, Lee JY, Saba JD, Trachtenberg E, et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003;101:351-357.

  10. Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. A new method. Va Med Mon (1918) 1972;99:276-280.

  11. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828-3832.

  12. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-1178.

  13. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003;101:4233-4244.

  14. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342:1846-1854.

  15. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962-2971.

  16. Sanz MA, Sanz GF. Unrelated donor umbilical cord blood transplantation in adults. Leukemia 2002;16:1984-1991.

  17. Frassoni F, Podesta M, Maccario R, et al. Cord blood transplantation provides better reconstitution of hematopoietic reservoir compared with bone marrow transplantation. Blood 2003;102:1138-1141.

  18. Talvensaari K, Clave E, Douay C, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002; 99:1458-1464.

  19. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000;25:131-133.

  20. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B. Editorial: ¿Why are mini-transplants being conducted worldwide? Rev Invest Clin Mex 2001;53:110-111.

  21. Giralt S, Estey E, Albitar M, van Besien K, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeoablative therapy. Blood 1997;89:4531-4536.

  22. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756-763.

  23. Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podesta M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998;83:904-909.

  24. Ruiz-Argüelles GJ. “The Mexican approach” to conduct non-myeloablative stem cell transplantation. Eur J Haematol 2001;67:335.

  25. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol 2002;76(Suppl 1):376-379.

  26. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001;66:241-244.

  27. Thomas ED. Hematopoietic stem cell transplantation. Sci Am 1995;272:38-47.

  28. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002;87:894-896.

  29. Ruiz-Argüelles GJ. Foro Clínico: El efecto de injerto contra tumor en leucemia granulocítica crónica. Rev Invest Clín Mex 2002;54:154-160.

  30. Gómez Almaguer D. The simplification of the stem cell transplantation procedures in developing countries has resulted in cost lowering and availability to more patients. Int J Hematol 2002;76(Suppl 1):380-382.

  31. Giralt S. Complications of non-myeloablative stem cell transplantation. In Giralt S, Slavin S (editors): Non-myeloablative stem cell transplantation. Abingdom, UK: Darwin Scientific Publishing; 2000. p.139-148.

  32. Ruiz-Argüelles GJ. Simplification, not demystification nor trivializacion of stem cell transplantation. Haematologica 2001;86:E07.

  33. Giralt S. Update on non-myeloablative stem cell transplantation for hematologic malignancies. Int J Hematol 2002;76(Suppl 1):368-375.

  34. Ruiz-Argüelles GJ, López-Martínez B, Estrada E, Marín-López A, Bravo G, Hernández JM. Autologous and allogeneic peripheral blood stem cell transplantations may be conducted without transfusion of blood products. Blood 2001;98(Suppl):351b.

  35. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-de-León S, Cantú-Rodríguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002;7:95-99.

  36. Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, Garcés-Eisele J. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single institution. Leukemia Lymph 2002;43:1509-1511.

  37. Gómez-Almaguer D, David Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Jaime-Pérez JC, López-Martínez B, Cantú-Rodríguez OG, Herrera-Garza JL. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transplant 2003;9:157-161.

  38. Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D, Estrada E, Marín-López A, Bravo-Hernández G, Hernández JM. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: A single institution experience. Hematology 2003;8:151-154.

  39. Ruiz-Argüelles GJ, López-Martínez B, López-Ariza B. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin´s disease following autologous stem cell transplantation. Arch Med Res 2003, en prensa.

  40. Ruiz-Argüelles GJ. Trasplante alogénico no mieloablativo (TANM): la experiencia de Puebla y Monterrey. Gac Med Mex 2003;139(Suppl 2):S151-S154.




2020     |     www.medigraphic.com